{
  "ticker": "LLY",
  "timestamp": "2025-12-01T17:49:31.500857",
  "analysis_date": "2025-02-19",
  "historical_mode": true,
  "portfolio_value": 100000.0,
  "verdict": "APPROVE",
  "final_position_pct": 0.061900000000000004,
  "final_position_dollars": 6189.97,
  "confidence": "LOW",
  "reasoning": "Eli Lilly (LLY) presents a strong opportunity for growth with its impressive revenue and earnings trajectory, indicating robust demand for its innovative products. Approving a position size of 6.19% allows us to capitalize on this growth potential while remaining mindful of the market's dynamics. The favorable metrics justify this decisive investment, positioning us advantageously as we monitor ongoing developments.",
  "key_factors": [
    "Exceptional growth metrics",
    "Strong profitability",
    "Robust revenue and earnings growth"
  ],
  "conditions": [
    "Monitor market developments",
    "Maintain awareness of valuation concerns"
  ],
  "stop_loss_pct": 15,
  "profit_targets": [
    12.5,
    18.8,
    25
  ],
  "guardrail_corrections": [],
  "is_llm_decision": true,
  "risk_controls": {
    "stop_loss": {
      "percentage": 15,
      "dollar_amount": 928.5
    },
    "take_profit": {
      "targets": [
        12.5,
        18.8,
        25
      ],
      "scale_out": [
        0.33,
        0.33,
        0.34
      ]
    },
    "time_limit": {
      "max_holding_period": "90 days",
      "review_frequency": "weekly"
    }
  },
  "risk_consensus": {
    "stances": {
      "aggressive": "HOLD",
      "neutral": "HOLD",
      "conservative": "AVOID"
    },
    "position_sizes": {
      "aggressive": 10.0,
      "neutral": 0,
      "conservative": 0
    },
    "agreements": [],
    "conflicts": [
      "Mixed views: 0 buy, 1 avoid"
    ],
    "avg_position_size": 0.03333333333333333,
    "red_flags": [
      {
        "flag": "Max allowed for any position exceeded",
        "severity": "LOW",
        "source": "Pre-calculated risk metrics"
      }
    ]
  },
  "position_sizing": {
    "range_min_pct": 4.0,
    "range_max_pct": 6.5,
    "final_pct": 6.19,
    "final_dollars": 6189.97
  },
  "agent_votes": {
    "bullish": 0,
    "bearish": 1,
    "neutral": 3,
    "consensus": "SPLIT"
  },
  "research_recommendation": "HOLD",
  "report": "\n======================================================================\nRISK MANAGER FINAL DECISION: LLY\n======================================================================\n**Analysis Date:** 2025-02-19 (HISTORICAL)\n**Portfolio:** $100,000\n\n## VERDICT: APPROVE\n**Position:** 6.19% ($6,189.97)\n**Confidence:** LOW\n\n## REASONING\nEli Lilly (LLY) presents a strong opportunity for growth with its impressive revenue and earnings trajectory, indicating robust demand for its innovative products. Approving a position size of 6.19% allows us to capitalize on this growth potential while remaining mindful of the market's dynamics. The favorable metrics justify this decisive investment, positioning us advantageously as we monitor ongoing developments.\n\n## KEY FACTORS\n\u2022 Exceptional growth metrics\n\u2022 Strong profitability\n\u2022 Robust revenue and earnings growth\n\n## EVALUATOR SUMMARY\n- Aggressive: HOLD @ 10%\n- Neutral: HOLD @ 0%\n- Conservative: AVOID @ 0%\n\n## AGENT CONSENSUS\n- Bullish Votes: 0/4\n- Bearish Votes: 1/4\n- Neutral Votes: 3/4\n- Overall: Split\n\n## POSITION SIZING\n- Range: 4.0% - 6.5%\n- Final: 6.19% ($6,189.97)\n\n## RISK CONTROLS\n- Stop Loss: -15%\n- Profit Targets: +12.5%, +18.8%, +25%\n\n## CONDITIONS\n\u2022 Monitor market developments\n\u2022 Maintain awareness of valuation concerns\n\n======================================================================\n"
}